Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Risk of fractures in patients with multiple sclerosis: a population-based cohort study.

Literature DB >> 23109656

Risk of fractures in patients with multiple sclerosis: a population-based cohort study.

Ruth Dobson, Sreeram Ramagopalan, Gavin Giovannoni, Marloes T Bazelier, Frank de Vries.

Abstract

Entities: Disease Species

Mesh：

Year: 2012 PMID： 23109656 DOI： 10.1212/01.wnl.0000422676.74031.07

Source DB: PubMed Journal: Neurology ISSN： 0028-3878 Impact factor: 9.910

Keyword Cloud
Cited

× No keyword cloud information.

3 in total

Review 1. Risk Factors, Epidemiology and Treatment Strategies for Metabolic Bone Disease in Patients with Neurological Disease.

Authors: S Binks; R Dobson
Journal: Curr Osteoporos Rep Date: 2016-10 Impact factor: 5.096

2. 1,25-Dihydroxyvitamin D suppresses M1 macrophages and promotes M2 differentiation at bone injury sites.

Authors: Samiksha Wasnik; Charles H Rundle; David J Baylink; Mohammad Safaie Yazdi; Edmundo E Carreon; Yi Xu; Xuezhong Qin; Kin-Hing William Lau; Xiaolei Tang
Journal: JCI Insight Date: 2018-09-06

3. Multiple Sclerosis Patients Show Lower Bioavailable 25(OH)D and 1,25(OH)₂D, but No Difference in Ratio of 25(OH)D/24,25(OH)₂D and FGF23 Concentrations.

Authors: Mariska C Vlot; Laura Boekel; Jolijn Kragt; Joep Killestein; Barbara M van Amerongen; Robert de Jonge; Martin den Heijer; Annemieke C Heijboer
Journal: Nutrients Date: 2019-11-15 Impact factor: 5.717

3 in total

Risk of fractures in patients with multiple sclerosis: a population-based cohort study.

Review 1. Risk Factors, Epidemiology and Treatment Strategies for Metabolic Bone Disease in Patients with Neurological Disease.

2. 1,25-Dihydroxyvitamin D suppresses M1 macrophages and promotes M2 differentiation at bone injury sites.

3. Multiple Sclerosis Patients Show Lower Bioavailable 25(OH)D and 1,25(OH)2D, but No Difference in Ratio of 25(OH)D/24,25(OH)2D and FGF23 Concentrations.

3. Multiple Sclerosis Patients Show Lower Bioavailable 25(OH)D and 1,25(OH)₂D, but No Difference in Ratio of 25(OH)D/24,25(OH)₂D and FGF23 Concentrations.